|1.||Sporn, Michael B: 22 articles (10/2015 - 07/2003)|
|2.||Liby, Karen T: 14 articles (10/2015 - 09/2004)|
|3.||Gribble, Gordon W: 8 articles (10/2015 - 07/2003)|
|4.||Honda, Tadashi: 8 articles (04/2011 - 07/2003)|
|5.||Kensler, Thomas W: 7 articles (07/2014 - 02/2006)|
|6.||Yamamoto, Masayuki: 6 articles (09/2015 - 01/2007)|
|7.||Suh, Nanjoo: 6 articles (01/2014 - 07/2003)|
|8.||Yates, Melinda S: 5 articles (11/2009 - 02/2006)|
|9.||Williams, Charlotte R: 4 articles (10/2015 - 07/2003)|
|10.||Sporn, Michael: 4 articles (09/2009 - 01/2004)|
10/01/2015 - "CDDO-2P-Im and CDDO-3P-Im were as effective as CDDO-Im for reducing the size and the severity of the lung tumors. "
07/01/2014 - "A lifetime cancer bioassay was undertaken in F344 rats dosed with AFB1 (200 μg/kg rat/day) for four weeks and receiving either vehicle or CDDO-Im (three times weekly), one week before and throughout the exposure period. "
09/01/2011 - "To this end, we developed a novel ligand-targeted nanoparticle (NP) encapsulating a CDDO-Im payload capable of specific delivery to the TME, which showed an effective therapeutic inhibition of STAT-3 activation in primary tumors. "
03/01/2011 - "Altogether, our results show that CDDO-Im induces ROS and subsequent DNA damage, thereby facilitating the activation of the DNA damage checkpoint, G2/M arrest, and finally apoptosis in BRCA1-mutated cancer cells. "
03/01/2011 - "However, the mechanisms responsible for the selective apoptotic effects of CDDO-Im in cancer cells remain elusive. "
|2.||Hepatocellular Carcinoma (Hepatoma)
07/01/2014 - "This study assessed and mechanistically characterized the chemoprotective efficacy of CDDO-Im against AFB1-induced hepatocellular carcinoma (HCC). "
07/01/2014 - "This study is notable for two reasons: (i) Activation of the Nrf2/Keap1/ARE "antioxidant response" pathway by CDDO-Im conferred complete protection against AFB-induced hepatocellular carcinomas in the Fisher F344 rat (a strain frequently used in life-time carcinogenicity bioassays), and (ii) extensive AFB-DNA adduct formation was seen in all animals at early time points, including those treated with CDDO-Im, albeit at lower levels (∼30% of the untreated animals), suggesting a strong divergence in the association between early DNA-damaging events, and tumor formation later in life. "
09/29/2015 - "Furthermore, administration of the Nrf2 inducer CDDO-Im (2-cyano-3, 12 dioxooleana-1, 9 diene-28-imidazolide) also relieved inflammation and organ failure in SCD mice. "
04/15/2011 - "To explore more potent N-acylimidazole analogues of CDDO than CDDO-Im, which is one of the most potent compounds in several widely used bioassays related to protection against inflammation and carcinogenesis; we have synthesized and evaluated five new N-acyl(acetylenic)imidazole analogues. "
12/01/2014 - "CDDO-Im attenuated IL-17 secretion in ex vivo models of inflammation. "
12/01/2014 - "In vivo, histological and biochemical parameters of colitis were improved in CDDO-Im treated mice. "
12/01/2014 - "Using a DSS colitis model, mice were dosed orally with vehicle or CDDO-Im (20 mg/kg) over a 5-day period. "
12/01/2014 - "The goals of our study were twofold: (1) To determine if ex vivo treatment with CDDO-Im attenuated colonic IL-17 secretion from isolated splenocytes and colonic strips; (2) To determine if oral treatment with CDDO-Im improved DSS-induced colitis in mice. "
12/01/2014 - "Subsequently, various parameters of colitis were determined on study day 6. Ex vivo treatment with CDDO-Im inhibited IL-17 secretion from splenocytes and colonic strips. "
12/01/2014 - "The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice."
|2.||Interleukin-17 (Interleukin 27)
|3.||DNA (Deoxyribonucleic Acid)
|4.||1,25- dihydroxy- 21- (3- hydroxy- 3- methyl- 4,4,4- tributyl)- 23- yne- 26,27- hexafluorocholecalciferol
|7.||Caspase 8 (Caspase-8)
|9.||1- (2- cyano- 3,12- dioxooleana- 1,9- dien- 28- oyl) imidazole
|4.||Heterologous Transplantation (Xenotransplantation)